Triple attack: new cell therapy combo takes on melanoma
NCT ID NCT06739226
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a combination of three immune cell therapies—CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell vaccines—against advanced melanoma that has not responded to standard treatment. The study aims to see if this approach is safe and can shrink tumors in 30 adult patients. Researchers will also monitor how long the immune cells last in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Combination of CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines targeting melanoma antigens
What this could lead to
If successful, this could offer a new treatment option for advanced melanoma that has not responded to standard therapy.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply broadly. Side effects from the cell therapies could be significant, and the combination may not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-Immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••